On #WorldBrainDay, we’re celebrating Tracey 💙
Diagnosed with glioblastoma, she joined a Roswell Park trial for the SurVaxM brain cancer vaccine.
3 years later, she’s still here, living life fully and feeling grateful.
Read more: https://t.co/51BE1L7w7m
This #GlioblastomaAwarenessDay, Dr. Ajay Abad of @RoswellPark highlights #SurVaxM, a novel survivin-targeted #vaccine for glioblastoma, and the importance of continued collaboration to move the needle forward in this aggressive disease.
Watch here! https://t.co/rP0Aw6sewR
💉SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility. @MimiVax_Inc is developing the novel vaccine @SurVaxM for the treatment of newly diagnosed #GBM. Disrupting cancer is our mission. #JPM25 https://t.co/cGhqfoXIah
Learn more about #SurVaxM and #GBM at https://t.co/FSm5Py4diw & check out our new animated mechanism of action video below. Discovered & Developed in #BuffaloNY@MimiVax_Inc@RoswellPark
Proud to be working side by side with @RoswellPark to bring new therapies to clinic for brain tumor patients #SurVaxM@MimiVax_Inc
https://t.co/eEzFgXhMnb
🔥Breaking News: US FDA awards Supplemental Orphan Drug Designation to @SurVaxM to now include treatment of Malignant Glioma. This is the second #ODD award for SurVaxM and now includes adult & pediatric malignant gliomas. #gbm#cancer#braintumor https://t.co/PnULhbYnWM
🩶It’s #GrayMay! This month, #GoGrayinMay to conquer and cure brain tumors — once and for all. Discover ways that you can make lasting change for the brain tumor community at https://t.co/CYXpSx9sCr. Follow @MimiVax_Inc to learn how @SurVaxM is improving current 🧠 therapy!
@MimiVaxLLC our goal is to #disruptcancer and shatter historical #data along the way! @SurVaxM is currently being studied for newly diagnosed #GBM in a a phase 2b clinical study at various sites across US. #cancervaccine#SNO2022@NeuroOnc https://t.co/GDgpLC8xhQ
The #immunotherapy SurVaxM shows promise in generating cytotoxic T lymphocytes, which may help in the treatment of #glioblastoma. This study gives hope to patients with this hard-to-treat form of #braincancer. #SNO2022
@SurVaxM is giving patients hope in rare disease. Our Phase 2b Clinical Study “SURVIVE” is showing very promising data. (SurVaxM mOS=25.9 months) Explore @MimiVaxLLC to learn more and see how we are #disruptingcancer#GBM#cancervaccine#SNO2022
Thank-you to our patients and their families who participated in the #SurVaxM Phase 2a trial. The journey continues in Phase 2b to bring SurVaxM another step closer to approval and #DisruptingCancer.
https://t.co/bFG6IrcLhd
⚠️Very excited to announce a collaboration focused on pediatric brain tumors! 🧠Roswell Park-Developed Immunotherapy Now Part of Nationwide Study in Kids With Brain Cancer | Roswell Park Comprehensive Cancer Center - Buffalo, NY #SurVaxM https://t.co/fuO5A01Mkk